You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD7 Positive

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia Trial in Beijing, Shenzhen,

Recruiting
  • T-cell Acute Lymphoblastic Leukemia
  • +3 more
  • Universal CD7-specific CAR gene-engineered T cells
  • Beijing, Beijing, China
  • +2 more
Aug 17, 2023

Tumors, Hematologic Tumors, Tumors by Site Trial in Wuhan (RD13-02 cell infusion)

Recruiting
  • Neoplasms
  • +3 more
  • RD13-02 cell infusion
  • Wuhan, Hubei, China
    Union Hospital, Huazhong University of Science and Technology
Jun 8, 2023

CD7+ Acute Leukemia, CD7+ Lymphoma Trial in Hangzhou (anti-CD7 CAR-T)

Recruiting
  • CD7+ Acute Leukemia
  • CD7+ Lymphoma
  • anti-CD7 CAR-T
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital，College of Medicine, Zhejiang Univ
Sep 18, 2022

Hematologic Diseases, Tumors Trial in Hangzhou (CD7 CAR-T cells injection, Allogeneic hematopoietic stem cell transplantation)

Recruiting
  • Hematologic Diseases
  • Neoplasms
  • CD7 CAR-T cells injection
  • Allogeneic hematopoietic stem cell transplantation
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Apr 11, 2023

Hematologic Malignancies Trial in Zhengzhou (RD13-02 cell infusion)

Recruiting
  • Hematologic Malignancies
  • RD13-02 cell infusion
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Jun 26, 2023

T Lymphoblastic Leukemia/Lymphoma, T-cell Acute Lymphoblastic Leukemia, Peripheral T Cell Lymphoma Trial in Shanghai (anti-CD7

Recruiting
  • T Lymphoblastic Leukemia/Lymphoma
  • +4 more
  • anti-CD7 CAR-T cells
  • Shanghai, China
    Xianmin General Song
Aug 29, 2022

Peripheral T Cell Lymphoma Trial in China (CAR-T Therapy)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • CAR-T Therapy
  • Hefei, Anhui, China
  • +7 more
Jul 31, 2023

Tumors, Hematologic Tumors, Tumors by Site Trial in Hangzhou (RD13-02 cell infusion)

Recruiting
  • Neoplasms
  • +3 more
  • RD13-02 cell infusion
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Feb 6, 2023

Tumors, Hematologic Tumors, Hematologic Diseases Trial in Xuzhou (RD13-02 cell infusion)

Recruiting
  • Neoplasms
  • +2 more
  • RD13-02 cell infusion
  • Xuzhou, Jiangsu, China
    Affiliated hospital of Xuzhou medical college
Jun 7, 2023

Tumors, Hematologic Tumors, Hematologic Diseases Trial in Hefei (RD13-02 cell infusion)

Recruiting
  • Neoplasms
  • +2 more
  • RD13-02 cell infusion
  • Hefei, Anhui, China
    The First Affiliated Hospital of University of Science and Techn
Jun 5, 2023

Leukemia, T Cell Trial in Beijing (CD7 CART)

Recruiting
  • Leukemia, T Cell
  • CD7 CART
  • Beijing, Hebei, China
    He bei Yan da Lu dao pei Hospital
May 24, 2022

CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies Trial in Hefei (T cell injection targeting CD7 chimeric

Recruiting
  • CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies
  • T cell injection targeting CD7 chimeric antigen receptor
  • Hefei, Anhui, China
    PersonGen.Anke Cellular Therapeutice Co., Ltd.
Dec 24, 2021

T-cell Acute Lymphoblastic Leukemia/Lymphoma Trial in Yanda (CD7 CAR-T)

Completed
  • T-cell Acute Lymphoblastic Leukemia/Lymphoma
  • CD7 CAR-T
  • Yanda, Hebei, China
    Hebei yanda Ludaopei Hospital
Jun 23, 2021

T-ALL Trial in Suzhou (T cell injection targeting CD7 chimeric antigen receptor)

Recruiting
  • T-ALL
  • T cell injection targeting CD7 chimeric antigen receptor
  • Suzhou, Jiangsu, China
    The First Affiliared Hospital Of SOOCHOW University
Mar 3, 2021

CAR, Malignant Tumors Trial in Hefei (Chimeric antigen receptor modified ?d T cells)

Recruiting
  • CAR
  • Malignant Tumors
  • Chimeric antigen receptor modified γδ T cells
  • Hefei, Anhui, China
    Anhui Provincial Hospital
Mar 4, 2021

T Lymphoblastic Leukemia/Lymphoma, Extramedullary NK-T-cell Lymphoma, Nasal Type, Peripheral T-cell Lymphoma, Nonspecific Trial

Recruiting
  • T Lymphoblastic Leukemia/Lymphoma
  • +6 more
  • T cell injection targeting CD7 chimeric antigen receptor
  • Zhengzhou, Henan, China
    First Affiliated Hospital of Zhengzhou University
Jan 4, 2021

HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Metastatic Breast Cancer Trial in Germany, Spain,

Recruiting
  • HER2-positive Breast Cancer
  • +4 more
  • Essen, Germany
  • +5 more
Nov 15, 2022

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Chronic Lymphocytic Leukemia Trial in Milwaukee (CAR-20/19-T cells (1.0 x10^5

Completed
Has Results
  • Lymphoma, Non-Hodgkin
  • +3 more
  • CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg)
  • +3 more
  • Milwaukee, Wisconsin
    Froedtert Hospital & Medical College of Wisconsin
Jun 26, 2022

Metastatic Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma Trial in Worldwide (MEN1309)

Terminated
Has Results
  • Metastatic Solid Tumors
  • Relapsed/Refractory Non-Hodgkin Lymphoma
  • Liège, Belgium
  • +6 more
Aug 31, 2021

Breast Cancer, Uterine Cancer, Ovarian Cancer Trial in Denmark, France, Spain (GEN1047 is a bispecific antibody that induces

Recruiting
  • Breast Cancer
  • +3 more
  • GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive cells.
  • Copenhagen, Denmark
  • +5 more
Jul 25, 2022

HER2-Positive Solid Tumors Trial (Chort 1 of M802, Chort 2 of M802, Cohort 3 of M802)

Not yet recruiting
  • HER2-Positive Solid Tumors
  • Chort 1 of M802
  • +7 more
  • (no location specified)
Jul 28, 2021

T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Trial (CD7-CART01)

Not yet recruiting
  • T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
  • CD7-CART01
  • (no location specified)
Sep 26, 2023

Hematological Malignancies Trial (Anti-CD7 CAR-T)

Not yet recruiting
  • Hematological Malignancies
  • Anti-CD7 CAR-T
  • (no location specified)
Jul 8, 2022

BRCA1 Gene Mutation, BRCA2 Gene Mutation, Folate Receptor Alpha Positive Trial in Columbus (other, biological, drug)

Active, not recruiting
  • BRCA1 Gene Mutation
  • +9 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Sep 16, 2022

Lymphoma Trial in Beijing (CD70-targeting CAR-T cells)

Recruiting
  • Lymphoma
  • CD70-targeting CAR-T cells
  • Beijing, Biotherapeutic Department Of Chinsese PLA Gereral Hospital, China
    China
Jul 9, 2023